Actinium Pharmaceuticals - ATNM Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATNM shares.
View ATNM analyst ratings or view top-rated stocks.

4 brokers have issued 1 year price targets for Actinium Pharmaceuticals' shares. Their ATNM share price forecasts range from $16.00 to $45.00. On average, they expect the company's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 259.1% from the stock's current price.
View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts.

Actinium Pharmaceuticals' stock was trading at $6.05 at the beginning of 2022. Since then, ATNM shares have increased by 22.0% and is now trading at $7.38.
View the best growth stocks for 2022 here.

Actinium Pharmaceuticals saw a decrease in short interest in September. As of September 15th, there was short interest totaling 352,500 shares, a decrease of 10.2% from the August 31st total of 392,700 shares. Based on an average trading volume of 139,200 shares, the short-interest ratio is presently 2.5 days.
View Actinium Pharmaceuticals' Short Interest.

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) issued its earnings results on Friday, August, 12th. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.10. The biotechnology company earned $0.05 million during the quarter, compared to analysts' expectations of $1.85 million. Actinium Pharmaceuticals had a negative net margin of 2,165.56% and a negative trailing twelve-month return on equity of 32.48%.

Actinium Pharmaceuticals shares reverse split on the morning of Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATNM stock can currently be purchased for approximately $7.38.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has a market capitalization of $185.87 million and generates $1.14 million in revenue each year.

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The official website for the company is www.actiniumpharmaceuticals.com. The biotechnology company can be reached via phone at (646) 677-3870 or via email at investorrelations@actiniumpharma.com.